Arcellx (ACLX) Net Income towards Common Stockholders (2021 - 2025)
Arcellx's (ACLX) quarterly Net Income towards Common Stockholders came in at -$58.0 million in Q4 2025, down 23.34% year-on-year from -$75.7 million in Q4 2024, and down 4.02% quarter-over-quarter from -$55.8 million in Q3 2025.
Arcellx (ACLX) Net Income towards Common Stockholders (2021 - 2025) Analysis & Trends
Arcellx's Net Income towards Common Stockholders history runs 5 years deep, the most recent figure standing at -$58.0 million for Q4 2025.
- On a quarterly basis, Net Income towards Common Stockholders fell 23.34% year-over-year to -$58.0 million in Q4 2025; TTM through Dec 2025 was -$228.8 million, a 113.33% decrease from a year earlier, with the FY2025 full-year figure at -$228.8 million, down 113.18% from the prior year.
- Net Income towards Common Stockholders slipped to -$58.0 million in Q4 2025 per ACLX's latest filing, from -$55.8 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $19.8 million in Q4 2023 and bottomed at -$92.9 million in Q3 2022.
- The 5-year median for Net Income towards Common Stockholders is -$29.1 million (2022), against an average of -$35.0 million.
- Across the five-year window, Net Income towards Common Stockholders surged 150.89% in 2023 and tumbled 765.1% in 2025, its largest moves.
- Year by year, Net Income towards Common Stockholders stood at -$59.4 million in 2021, then soared by 34.4% to -$39.0 million in 2022, then jumped by 150.89% to $19.8 million in 2023, then slumped by 337.07% to -$47.0 million in 2024, then retreated by 23.34% to -$58.0 million in 2025.
- Per Business Quant, the three latest ACLX Net Income towards Common Stockholders figures stand at -$58.0 million (Q4 2025), -$55.8 million (Q3 2025), and -$52.8 million (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -625.73 |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -0.68 |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 366.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Arcellx | 6.48 Bn | 6.48 Bn | - | -58.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -58.02 Mn |
| Sep 30, 2025 | -55.78 Mn |
| Jun 30, 2025 | -52.77 Mn |
| Mar 31, 2025 | -62.27 Mn |
| Dec 31, 2024 | -47.05 Mn |
| Sep 30, 2024 | -25.87 Mn |
| Jun 30, 2024 | -27.16 Mn |
| Mar 31, 2024 | -7.20 Mn |
| Dec 31, 2023 | 19.84 Mn |
| Sep 30, 2023 | -39.34 Mn |
| Jun 30, 2023 | -23.84 Mn |
| Mar 31, 2023 | -27.34 Mn |
| Dec 31, 2022 | -38.99 Mn |
| Sep 30, 2022 | -92.87 Mn |
| Jun 30, 2022 | -30.77 Mn |
| Mar 31, 2022 | -26.04 Mn |
| Dec 31, 2021 | -59.44 Mn |
| Sep 30, 2021 | -17.12 Mn |
| Jun 30, 2021 | -15.93 Mn |
| Mar 31, 2021 | -11.28 Mn |